Literature DB >> 36038272

Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.

Christian Cordano1, Bardia Nourbakhsh2, Hao H Yiu2, Nico Papinutto2, Eduardo Caverzasi2, Ahmed Abdelhak2, Frederike C Oertel2, Alexandra Beaudry-Richard2, Adam Santaniello2, Simone Sacco2, Daniel J Bennett2, Apraham Gomez2, Christina J Sigurdson2, Stephen L Hauser2, Roberta Magliozzi2, Bruce A C Cree2, Roland G Henry2, Ari J Green2.   

Abstract

BACKGROUND AND OBJECTIVES: The timing of neurodegeneration in multiple sclerosis (MS) remains unclear. It is critical to understand the dynamics of neuroaxonal loss if we hope to prevent or forestall permanent disability in MS. We therefore used a deeply phenotyped longitudinal cohort to assess and compare rates of neurodegeneration in retina and brain throughout the MS disease course.
METHODS: We analyzed 597 patients with MS who underwent longitudinal optical coherence tomography imaging annually for 4.5 ± 2.4 years and 432 patients who underwent longitudinal MRI scans for 10 ± 3.4 years, quantifying macular ganglion cell-inner plexiform layer (GCIPL) volume and cortical gray matter (CGM) volume. The association between the slope of decline in the anatomical structure and the age of entry in the cohort (categorized by the MRI cohort's age quartiles) was assessed by hierarchical linear models.
RESULTS: The rate of CGM volume loss declined with increasing age of study entry (1.3% per year atrophy for the age of entry in the cohort younger than 35 years; 1.1% for older than 35 years and younger than 41; 0.97% for older than 41 years and younger than 49; 0.9% for older than 49 years) while the rate of GCIPL thinning was highest in patients in the youngest quartile, fell by more than 50% in the following age quartile, and then stabilized (0.7% per year thinning for the age of entry in the cohort younger than 35 years; 0.29% for age older than 35 and younger than 41 years; 0.34% for older than 41 and younger than 49 years; 0.33% for age older than 49 years). DISCUSSION: An age-dependent reduction in retinal and cortical volume loss rates during relapsing-remitting MS suggests deceleration in neurodegeneration in the earlier period of disease and further indicates that the period of greatest adaptive immune-mediated inflammatory activity is also the period with the greatest neuroaxonal loss.
© 2022 American Academy of Neurology.

Entities:  

Mesh:

Year:  2022        PMID: 36038272      PMCID: PMC9559941          DOI: 10.1212/WNL.0000000000200977

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  38 in total

Review 1.  Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis.

Authors:  Elliot M Frohman; Fiona Costello; Olaf Stüve; Peter Calabresi; David H Miller; Simon J Hickman; Robert Sergott; Amy Conger; Amber Salter; Kimberly H Krumwiede; Teresa C Frohman; Laura Balcer; Robert Zivadinov
Journal:  Arch Neurol       Date:  2008-01

2.  Profile and predictors of normal ganglion cell-inner plexiform layer thickness measured with frequency-domain optical coherence tomography.

Authors:  Jean-Claude Mwanza; Mary K Durbin; Donald L Budenz; Christopher A Girkin; Christopher K Leung; Jeffrey M Liebmann; James H Peace; John S Werner; Gadi Wollstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-04       Impact factor: 4.799

Review 3.  Comparing the efficacy of disease-modifying therapies in multiple sclerosis.

Authors:  Dimos D Mitsikostas; Douglas S Goodin
Journal:  Mult Scler Relat Disord       Date:  2017-08-18       Impact factor: 4.339

4.  Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.

Authors:  Shiv Saidha; Omar Al-Louzi; John N Ratchford; Pavan Bhargava; Jiwon Oh; Scott D Newsome; Jerry L Prince; Dzung Pham; Snehashis Roy; Peter van Zijl; Laura J Balcer; Elliot M Frohman; Daniel S Reich; Ciprian Crainiceanu; Peter A Calabresi
Journal:  Ann Neurol       Date:  2015-10-01       Impact factor: 10.422

Review 5.  Pathological mechanisms in progressive multiple sclerosis.

Authors:  Don H Mahad; Bruce D Trapp; Hans Lassmann
Journal:  Lancet Neurol       Date:  2015-02       Impact factor: 44.182

6.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

Authors:  Roberta Magliozzi; Owain Howell; Abhilash Vora; Barbara Serafini; Richard Nicholas; Maria Puopolo; Richard Reynolds; Francesca Aloisi
Journal:  Brain       Date:  2007-04       Impact factor: 13.501

7.  Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.

Authors:  Jeffrey Lambe; Hunter Risher; Angeliki G Filippatou; Olwen C Murphy; Elias S Sotirchos; Henrik Ehrhardt; Esther Ogbuokiri; Nicole Pellegrini; Brandon Toliver; Nicholas J Luciano; Simidele Davis; Nicholas Fioravante; Ohemaa Kwakyi; Jerry L Prince; Peter A Calabresi; Kathryn C Fitzgerald; Shiv Saidha
Journal:  Neurology       Date:  2021-04-07       Impact factor: 9.910

8.  Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.

Authors:  Jeffrey Lambe; Kathryn C Fitzgerald; Olwen C Murphy; Angeliki G Filippatou; Elias S Sotirchos; Grigorios Kalaitzidis; Elena Vasileiou; Nicole Pellegrini; Esther Ogbuokiri; Brandon Toliver; Nicholas J Luciano; Simidele Davis; Nicholas Fioravante; Ohemaa Kwakyi; Hunter Risher; Ciprian M Crainiceanu; Jerry L Prince; Scott D Newsome; Ellen M Mowry; Shiv Saidha; Peter A Calabresi
Journal:  Neurology       Date:  2021-03-02       Impact factor: 9.910

9.  Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis.

Authors:  Tobias Zrzavy; Simon Hametner; Isabella Wimmer; Oleg Butovsky; Howard L Weiner; Hans Lassmann
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

10.  The relation between inflammation and neurodegeneration in multiple sclerosis brains.

Authors:  Josa M Frischer; Stephan Bramow; Assunta Dal-Bianco; Claudia F Lucchinetti; Helmut Rauschka; Manfred Schmidbauer; Henning Laursen; Per Soelberg Sorensen; Hans Lassmann
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.